Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCorRx Inc BICX

Healthcare
BioCorRx Inc., through its subsidiaries, develops and provides addiction treatment solutions for the treatment of substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent... see more

Recent & Breaking News (OTCQB:BICX)

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

GlobeNewswire April 3, 2024

BioCorRx Reports Business Update for 2023

GlobeNewswire April 2, 2024

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD

GlobeNewswire February 28, 2024

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

GlobeNewswire February 8, 2024

BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President

GlobeNewswire January 9, 2024

BioCorRx Reports Business Update for the Third Quarter of 2023

GlobeNewswire November 14, 2023

BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder

GlobeNewswire August 15, 2023

BioCorRx Reports Business Update for the Second Quarter of 2023

GlobeNewswire August 14, 2023

BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder

GlobeNewswire July 18, 2023

BioCorRx Provides Business Update for the First Quarter of 2023

GlobeNewswire May 16, 2023

BioCorRx Provides Business Update for 2022

GlobeNewswire April 3, 2023

BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting

GlobeNewswire March 7, 2023

BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data

GlobeNewswire February 23, 2023

BioCorRx to Present at Sequire Biotechnology Conference on February 2nd

GlobeNewswire January 27, 2023

BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors

GlobeNewswire January 24, 2023

BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

GlobeNewswire January 19, 2023

Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors

GlobeNewswire January 11, 2023

BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

GlobeNewswire December 7, 2022

BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.

GlobeNewswire November 22, 2022

BioCorRx Provides Business Update for the Third Quarter of 2022

GlobeNewswire November 15, 2022